Leadership

Mylan N.V. is a publicly traded company on the NASDAQ Global Select Market and incorporated under the laws of the Netherlands, as set forth in its Articles of Association. 

The chief executive officer and other executive officers of Mylan N.V. carry out the day-to-day conduct of Mylan N.V.'s worldwide businesses at the company's principal offices in Canonsburg, Pennsylvania. Duties and standards of conduct for Mylan employees, officers and directors are set forth in the company’s Code of Business Conduct and Ethics, as well as in the Code of Ethics for the chief executive officer, chief financial officer and corporate controller. 

Mylan N.V. is managed and controlled under the oversight of the company's board of directors in the United Kingdom, where the board generally meets. The board has established eight committees, each of which operates pursuant to a written charter. Each director is elected annually by the company’s shareholders. Certain of the directors’ duties, rights and responsibilities are detailed in the company’s Articles of Association, Board Rules, and Corporate Governance Principles.



Board of Directors

  • Heather Bresch

    Chief Executive Officer
    Mylan


    Executive Director

    Heather Bresch was elected to the board of directors of Mylan in 2011. She is a member of Mylan’s Science and Technology Committee.

    Bresch has served as Mylan’s CEO since January 1, 2012. Throughout her 26-year career with Mylan, Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as the company’s president, where she was responsible for its day-to-day operations. Before that, she served as chief operating officer and chief integration officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled Mylan’s size and transformed it from a purely U.S. company to a global one.

    As CEO, Bresch has been leading the next chapter of Mylan’s growth and performance, pursuing a strategy that already has produced a sustainable organization that is making great strides in its mission of delivering better health for a better world by providing 7 billion people access to high quality medicine. In continuing to execute on this strategy, Bresch is focused on further diversifying the company in terms of products, markets and channels, a process proven to expand access and generate durable cash flows that can be reinvested to further differentiate Mylan and position it to support the transformation of outdated healthcare systems.

    To achieve Mylan’s goals, Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare. She also remains a vocal champion of initiatives and policy changes aimed at removing access barriers. Among her policy priorities is increasing generic utilization, driving biosimilars interchangeability, stemming the tide of HIV/AIDS, ensuring a fair and a level competitive playing field, and strengthening the global supply chain to make it safer.

    Bresch served as chair of the U.S. Generic Pharmaceutical Association’s* board of directors in 2016, 2005 and 2004, and as vice chair in 2003 and 2006. She is a frequent speaker on issues such as affordable healthcare and global competitiveness, and has testified before the U.S. Congress and the U.S. Food and Drug Administration on issues related to access to medicine. Bresch is the pharmaceutical industry’s first female CEO of a Fortune 500 company and has been named by Fortune magazine as one of its “50 Most Powerful Women.”

    * The Generic Pharmaceutical Association was renamed Association for Accessible Medicines in February 2017.

  • Robert J. Cindrich*

    President
    Cindrich Consulting


    Non-Executive Director

    Robert Cindrich was elected to the board of directors of Mylan in 2011. He is a member of Mylan's Compliance, Governance and Nominating, Risk Oversight, and Science and Technology Committees.

    Since February 2011, Cindrich has been serving as president of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance and business strategies. From Oct. 1, 2013, through Jan. 31, 2014, he served as interim general counsel for United States Steel Corporation (U.S. Steel) (NYSE: X), an integrated steel producer of flat-rolled and tubular products. Cindrich joined Schnader Harrison Segal & Lewis (Schnader), a law firm, as legal counsel in April 2013 and took a temporary leave of absence on Oct. 1, 2013, to join U.S. Steel as interim general counsel, returning to Schnader after his time there and remaining until December 2017. In May 2012, he joined the board of directors of Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), which provides healthcare information technology solutions, where he served until April 2015. From 2011 through 2012, Cindrich served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center (UPMC), an integrated global health enterprise. From 2004 through 2010, Cindrich was a senior vice president and the chief legal officer of UPMC. From 1994 through January 2004, Cindrich served as a judge on the U.S. District Court for the Western District of Pennsylvania. Prior to that appointment, he was active as an attorney in government and private practice, including positions as the U.S. Attorney for the Western District of Pennsylvania and as the Allegheny County Assistant Public Defender and Assistant District Attorney.

  • Robert J. Coury

    Chairman
    Mylan
     
    Non-Executive Director

    Robert J. Coury is the Chairman of Mylan N.V. Under his visionary leadership, Mylan has transformed from the third largest generics pharmaceutical company in the U.S. into one of the largest pharmaceutical companies in the world, earning spots in both the S&P 500 and, prior to the company’s reincorporation outside of the U.S. in 2015, the Fortune 500. 

    Coury was first elected to Mylan’s board of directors in February 2002, having served since 1995 as a strategic advisor to the company. He became the board’s vice chairman shortly after his election, served as CEO from September 2002 until January 2012. Coury then served as executive chairman from 2012 until he became chairman in June 2016.

    Since 2007, Coury has led the company through a series of transactions totaling more than $25 billion, which transformed Mylan into a global powerhouse within the highly competitive pharmaceutical industry. The company has a workforce of more than 35,000 and sells products in more than 165 countries.

    In 2007, Mylan purchased India-based Matrix Laboratories, a major producer of active pharmaceutical ingredients, and the generics business of Europe-based Merck KGaA. Subsequent acquisitions under Coury’s leadership further expanded the company into new therapeutic categories and greatly enhanced its geographic and commercial footprint. In 2010, Mylan acquired Bioniche Pharma, a global injectables business in Ireland; in 2012, Mylan acquired India-based Agila Specialties, a global injectables company; and in 2015, Mylan acquired Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business and Famy Care’s women’s healthcare businesses. In 2016, Mylan acquired Meda, a leading international specialty pharmaceutical company that sells both prescription and over-the-counter products.   

    During this period of expansion, the company built an unmatched, high quality foundation for the future supporting Mylan’s mission of providing the world’s 7 billion people with access to high quality medicine and benefiting patients, customers, investors, and other stakeholders. 

    Before becoming executive chairman in 2012, Coury also executed a successful executive leadership transition after cultivating and developing a powerful leadership team. Grooming executive talent from within and recruiting dynamic leaders from outside the company were both key components of the company’s past, current and future growth strategies. 

    Prior to joining Mylan, Coury was the principal of Coury Consulting, a boutique business advisory firm he formed in 1989, and The Coury Financial Group, a successful financial and estate planning firm, which he founded in 1984. 

    Coury is also the founder and president of the Robert J. Coury Family Foundation, which is a charitable organization formed to help support his philanthropic efforts and his mission of giving back. He has served as a member of the University of Southern California President's Leadership Council since 2014. 

    Coury earned a Bachelor of Science degree in industrial engineering from the University of Pittsburgh.              


  • JoEllen Lyons Dillon*

    Former Chief Legal Officer
    and Corporate Secretary
    The ExOne Company

     

    Non-Executive Director

    JoEllen Lyons Dillon was elected to the board of directors of Mylan in 2014. She is a member of Mylan’s Audit and Executive Committees and serves as chair of both its Compensation and Governance and Nominating Committees.

    Dillon served most recently as chief legal officer and corporate secretary of The ExOne Company (ExOne) (NASDAQ: XONE), a global provider of three-dimensional printing machines, from March 2013 to August 2017, and as executive vice president from December 2014 to August 2017. Previously, she was a legal consultant on ExOne’s initial public offering. Prior to that, Dillon was a partner with Reed Smith LLP, a law firm, from 2002 until 2011. She previously had been at the law firm Buchanan Ingersoll & Rooney PC from 1988 until 2002, where she became a partner in 1997. Dillon is a member of the board of trustees of the Allegheny District chapter of the National Multiple Sclerosis Society and has previously served as board chair and audit committee chair.

  • Neil Dimick*

    Retired Executive Vice President
    and Chief Financial Officer
    AmerisourceBergen Corporation


    Non-Executive Director

    Neil Dimick was elected to the board of directors of Mylan in 2005. He is a member of Mylan’s Executive, Finance and Risk Oversight Committees and serves as chair of its Audit Committee.

    Currently retired, Dimick previously served as executive vice president and chief financial officer of AmerisourceBergen Corporation (NYSE: ABC), a wholesale distributor of pharmaceuticals, from 2001 to 2002. From 1992 to 2001, he was senior executive vice president and chief financial officer of Bergen Brunswig Corporation, a wholesale drug distributor. Prior to that, Dimick served as a partner with Deloitte & Touche LLP (Deloitte) for eight years. Dimick also serves on the board of directors of Resources Connection, Inc. (NASDAQ: RECN). Dimick also served on the boards of directors of WebMD Health Corp. from 2005 to September 2017, at which time it was purchased by Internet Brands, a portfolio company of investment funds affiliated with Kohlberg Kravis Roberts & Co., LP; Alliance HealthCare Services, Inc. from 2002 to August 2017, at which time it was purchased by Tahoe Investment Group Co., Ltd.; and Thoratec Corporation from 2003 to October 2015, at which time it was purchased by St. Jude Medical, Inc.

  • Melina Higgins*

    Former Partner
    Goldman Sachs


    Non-Executive Director

    Melina Higgins was elected to the board of directors of Mylan in 2013. She is a member of Mylan’s Audit and Compensation Committees and serves as chair of its Finance Committee.

    Currently retired, Higgins held senior roles of increasing responsibility at The Goldman Sachs Group, Inc. (NYSE: GS), a global investment banking, securities and investment management firm, including partner and managing director, during her nearly 20-year career at the firm from 1989 to 1992 and 1994 to 2010. During her tenure there, Higgins served as a member of the Investment Committee of the Principal Investment Area, which oversaw and approved global private equity and private debt investments and was one of the largest alternative asset managers in the world. She also served as head of the Americas and as co-chairperson of the Investment Advisory Committee for GS Mezzanine Partners funds, which managed more than $30 billion of assets and were global leaders in their industry. Higgins also is a member of the Women’s Leadership Board of Harvard University’s John F. Kennedy School of Government. In September 2013, Higgins joined the board of directors of Genworth Financial Inc. (NYSE: GNW), an insurance company. In January 2016, Higgins became non-executive chairman of Antares Midco Inc., a private company that provides financing solutions for middle-market, private equity-backed transactions.

  • Harry A. Korman*

    Retired Chief Operating Officer
    Mylan

     

    Non-Executive Director

    Harry A. Korman was elected to the board of directors of Mylan in 2018. He is a member of Mylan's Compliance and Science and Technology Committees and serves as chair of its Risk Oversight Committee.

    Currently retired, Korman previously held senior executive roles of increasing responsibility at Mylan Inc. and its subsidiaries from 1996 until July 2014. He served as Mylan's chief operating officer from January 2012 until his retirement in July 2014, after which he served in a consultant role with Mylan for one year. Prior to his service as chief operating officer, he was the president of Mylan North America beginning in October 2007. Korman also served as president of Mylan Pharmaceuticals Inc. from February 2005 to December 2009. During his time as an executive at Mylan, Korman was instrumental in identifying, evaluating and executing on significant commercial and business development opportunities in the United States and other countries, including the expansion of Mylan’s global generics businesses around the world, among many other important contributions to the company and its stakeholders. He joined Mylan in 1996 after the company’s acquisition of UDL Laboratories (n/k/a Mylan Institutional) and served as its president, among other prior responsibilities. Korman has served as a past director and vice chairman of the Generic Pharmaceutical Association, now known as the Association for Accessible Medicines. He also previously served as a director and vice chairman of the HDMA Foundation, which serves the healthcare industry by providing research and education focused on healthcare supply issues.

  • Rajiv Malik

    President
    Mylan


    Executive Director

    Rajiv Malik was elected to the board of directors of Mylan in 2013. He is a member of Mylan’s Science and Technology Committee.

    Malik has served as Mylan’s president since Jan 1, 2012, and has more than 35 years of experience in the pharmaceutical industry. Previously, Malik held various senior roles at Mylan, including executive vice president and chief operating officer from July 2009 to December 2012, and head of Global Technical Operations from January 2007 to July 2009. Malik has been integral in developing the strategies for the company’s acquisitions and, more importantly, in the execution and integration of acquisitions, specifically the generics business of Merck KGaA; the injectables business of Bioniche Pharma; Agila Specialties, a global injectables company; the Abbott EPD business; Famy Care’s women’s healthcare businesses; Meda, a leading international specialty pharmaceutical company that sells prescription and over-the-counter products; and most recently, the non-sterile, topicals-focused business of Renaissance Acquisition Holdings LLC.

    Malik oversees the day-to-day operations of the company, which includes Commercial, Scientific Affairs, Manufacturing, Supply Chain and Quality as well as Business Development and Information Technology. Malik has been instrumental in expanding and optimizing Mylan’s product portfolio, leveraging Mylan’s global research and development capabilities and expanding Mylan’s presence in emerging markets. Previously, he served as chief executive officer of Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) from July 2005 to June 2008. Prior to joining Matrix, he served as head of global development and registrations for Sandoz GmbH from September 2003 to July 2005. Prior to joining Sandoz GmbH, Malik was head of Global Regulatory Affairs and head of Pharma Research for Ranbaxy from October 1999 to September 2003.

  • Mark W. Parrish*

    Chairman and CEO
    Trident USA Health Services


    Non-Executive Director

    Mark W. Parrish was elected to the board of directors of Mylan in 2009 and currently serves as the lead independent director and vice chairman. He is a member of Mylan’s Audit, Executive, Governance and Nominating and Risk Oversight Committees and serves as chair of its Compliance Committee.

    Parrish has served as the lead independent director and vice chairman of Mylan’s Board since August 2017. He has served as chief executive officer of TridentUSA Health Services, a provider of mobile X-ray and laboratory services to the long-term care industry, since 2008 and served as chairman from 2008 to 2013. Since January 2013, Parrish also has served on the board of directors of Omnicell, Inc. (NASDAQ: OMCL), a company that specializes in healthcare technology. Parrish also serves on the boards of directors of Silvergate Pharmaceuticals, a private company that develops and commercializes pediatric medications; and GSMS, a private company that specializes in meeting unique labeling and sizing needs for its customers and pharmaceutical packaging, serialization and distribution. From 2001 to 2007, Parrish held management roles of increasing responsibility with Cardinal Health Inc. (NYSE: CAH) and its affiliates, including chief executive officer of Healthcare Supply Chain Services for Cardinal from 2006 to 2007. Parrish also serves as president of the International Federation of Pharmaceutical Wholesalers, an association of pharmaceutical wholesalers and pharmaceutical supply chain service companies and as senior adviser to Frazier Healthcare Ventures, a healthcare-oriented growth equity firm.

  • Randall L. Vanderveen, Ph.D.*

    Retired Professor and Senior Advisor
    USC Leonard D. Schaeffer Center
    for Health Policy & Economics
    Former Director, Biles Leadership Center

     

    Non-Executive Director

    Randall “Pete” Vanderveen was elected to the board of directors of Mylan in 2002. He is a member of Mylan’s Compliance Committee and serves as chair of its Science and Technology Committee.

    Currently retired, Vanderveen most recently was professor of Pharmaceutical Policy and Economics, senior adviser to the Leonard D. Schaeffer Center of Health Policy and Economics, director of the Margaret and John Biles Center for Leadership, and senior adviser to the dean for Advancement at the School of Pharmacy, University of Southern California in Los Angeles, from 2015 to August 2017. Vanderveen previously served as dean, professor and John Stauffer Decanal Chair of the USC School of Pharmacy from 2005 to 2015, where he was named “Outstanding Pharmacy Dean in the Nation” in 2013 by the American Pharmacist Association. From 1998 to 2005, he served as dean and professor of Pharmacy of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University, before which he was assistant dean at Oregon State University from 1988 to 1998. Vanderveen has an extensive pharmaceutical and academic background. In addition, Vanderveen has invaluable experience and knowledge regarding the business, platforms, strategies, challenges, opportunities and management of Mylan, among other matters.

  • Pauline van der Meer Mohr*

    Independent Non-Executive Director, HSBC Holdings plc
    Supervisory Board, Royal DSM N.V.
    and EY Netherlands LLP 

     

    Non-Executive Director

    Pauline van der Meer Mohr was elected to the board of directors of Mylan in 2018. She is a member of Mylan's Compensation and Risk Oversight Committees.

    Van der Meer Mohr is currently an independent non-executive director of HSBC Holdings plc (LON: HSBA), chairing that company’s Group Remuneration Committee and serving as a member of its Group Risk Committee and Nomination Committee. She also is a member of the supervisory boards of Royal DSM N.V. (AMS: DSM), currently serving as vice chairman, chairing its Remuneration Committee and serving on its Nomination Committee, and EY Netherlands LLP, currently serving as chair. Van der Meer Mohr recently served on the supervisory board of ASML Holding N.V. (NASDAQ and AMS: ASML) until April 2018 and as president of the Executive Board of Erasmus University in Rotterdam from 2010 to 2016. Van der Meer Mohr began her career in the legal profession and previously held several legal and management positions within Royal Dutch Shell Group from 1989 to 2004. In 2004, she was appointed group human resources director at TNT N.V. before becoming senior executive vice president and head of group human resources at ABN AMRO N.V. in 2006. She served as a member of the Dutch Banking Code Monitoring Commission in the Netherlands from 2010 to 2013 and began her own human capital consulting firm in 2008.

  • Sjoerd S. Vollebregt*

    Chairman of the Supervisory Board of Heijmans N.V.


    Non-Executive Director

    Sjoerd Vollebregt was elected to the board of directors of Mylan in 2017. He is a member of Mylan’s Compliance, Finance, and Governance and Nominating Committees.

    Vollebregt has been chairman of the Supervisory Board of Heijmans N.V., a Euronext Amsterdam-listed company that operates in property development, residential building, non-residential building, roads and civil engineering since 2015; chairman of the Advisory Board of Airbus Defence and Space Netherlands B.V., a subsidiary of Airbus SE, a Euronext Paris-listed company that develops solar arrays, satellite instruments and structures for launchers since 2015; and chairman of the Economic Development Board Drecht Cities, a strategic collaboration between business, education and government in Drecht Cities, Netherlands, since December 2016. Vollebregt had served as chairman of the Executive Board of Stork B.V. and its predecessor from 2002 to 2014. Stork was an Amsterdam Stock Exchange-listed industrial group until 2008 consisting of a global provider of knowledge-based maintenance, modification and asset integrity products and services, food and textile equipment manufacturer. He also served as chief executive officer of Fokker Technologies Group B.V., an aerospace company, and a Stork B.V. subsidiary from 2010 to 2014. Previously, Vollebregt served as a member of the Supervisory Board of TNT Express N.V., an international courier delivery services company, from 2013 to 2016, and has held various other senior positions at Excel plc, Ocean plc, Intexo Holding and Royal Van Ommeren.

*Independent director

Executive Management

  • Heather Bresch

    Chief Executive Officer
    Mylan


    Executive Director

    Heather Bresch was elected to the board of directors of Mylan in 2011. She is a member of Mylan’s Science and Technology Committee.

    Bresch has served as Mylan’s CEO since January 1, 2012. Throughout her 26-year career with Mylan, Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as the company’s president, where she was responsible for its day-to-day operations. Before that, she served as chief operating officer and chief integration officer, leading the successful integration of two international acquisitions – Matrix Laboratories and Merck KGaA’s generics business – which more than doubled Mylan’s size and transformed it from a purely U.S. company to a global one.

    As CEO, Bresch has been leading the next chapter of Mylan’s growth and performance, pursuing a strategy that already has produced a sustainable organization that is making great strides in its mission of delivering better health for a better world by providing 7 billion people access to high quality medicine. In continuing to execute on this strategy, Bresch is focused on further diversifying the company in terms of products, markets and channels, a process proven to expand access and generate durable cash flows that can be reinvested to further differentiate Mylan and position it to support the transformation of outdated healthcare systems.

    To achieve Mylan’s goals, Bresch emphasizes a collaborative company culture focused on leading, learning, teaching and performing to inspire innovation and help set new standards in healthcare. She also remains a vocal champion of initiatives and policy changes aimed at removing access barriers. Among her policy priorities is increasing generic utilization, driving biosimilars interchangeability, stemming the tide of HIV/AIDS, ensuring a fair and a level competitive playing field, and strengthening the global supply chain to make it safer.

    Bresch served as chair of the U.S. Generic Pharmaceutical Association’s* board of directors in 2016, 2005 and 2004, and as vice chair in 2003 and 2006. She is a frequent speaker on issues such as affordable healthcare and global competitiveness, and has testified before the U.S. Congress and the U.S. Food and Drug Administration on issues related to access to medicine. Bresch is the pharmaceutical industry’s first female CEO of a Fortune 500 company and has been named by Fortune magazine as one of its “50 Most Powerful Women.”

    * The Generic Pharmaceutical Association was renamed Association for Accessible Medicines in February 2017.

  • Rajiv Malik

    President
    Mylan


    Executive Director

    Rajiv Malik was elected to the board of directors of Mylan in 2013. He is a member of Mylan’s Science and Technology Committee.

    Malik has served as Mylan’s president since Jan 1, 2012, and has more than 35 years of experience in the pharmaceutical industry. Previously, Malik held various senior roles at Mylan, including executive vice president and chief operating officer from July 2009 to December 2012, and head of Global Technical Operations from January 2007 to July 2009. Malik has been integral in developing the strategies for the company’s acquisitions and, more importantly, in the execution and integration of acquisitions, specifically the generics business of Merck KGaA; the injectables business of Bioniche Pharma; Agila Specialties, a global injectables company; the Abbott EPD business; Famy Care’s women’s healthcare businesses; Meda, a leading international specialty pharmaceutical company that sells prescription and over-the-counter products; and most recently, the non-sterile, topicals-focused business of Renaissance Acquisition Holdings LLC.

    Malik oversees the day-to-day operations of the company, which includes Commercial, Scientific Affairs, Manufacturing, Supply Chain and Quality as well as Business Development and Information Technology. Malik has been instrumental in expanding and optimizing Mylan’s product portfolio, leveraging Mylan’s global research and development capabilities and expanding Mylan’s presence in emerging markets. Previously, he served as chief executive officer of Matrix Laboratories Limited (n/k/a Mylan Laboratories Limited) from July 2005 to June 2008. Prior to joining Matrix, he served as head of global development and registrations for Sandoz GmbH from September 2003 to July 2005. Prior to joining Sandoz GmbH, Malik was head of Global Regulatory Affairs and head of Pharma Research for Ranbaxy from October 1999 to September 2003.

  • Anthony Mauro

    Chief Commercial Officer

    Mylan

    Anthony (Tony) Mauro is Mylan’s Chief Commercial Officer (CCO) overseeing all of its commercial businesses around the world. As CCO, Mauro is responsible for leveraging Mylan’s diverse portfolio, pipeline and expansive commercial infrastructure to drive business growth across multiple markets and channels.

    Mauro has been with Mylan for more than 20 years. He has served the company in several capacities of increasing responsibility. Most recently, he served as president of North America, successfully leading the company’s largest commercial business. Prior to that role, Mauro served as president of Mylan Pharmaceuticals Inc., the company's flagship generics division in the U.S.; chief operating officer of Mylan Pharmaceuticals ULC in Canada; vice president of North America Strategic Development; and vice president of North America Sales. 

    In 2012 and 2013, Mauro served as chairman of the board of directors for the U.S. Generic Pharmaceutical Association (GPhA), which represents the world's leading generic drug manufacturers and suppliers. Prior to that he served two consecutive terms as vice chairman of the board for GPhA, now known as the Association for Accessible Medicines. 

    Mauro is a member of the visiting committee at West Virginia University's Graduate School of Business and Economics. Mauro earned a bachelor's degree in business administration, with a specialization in finance, and a master's degree in business administration from West Virginia University.

  • Ken Parks

    Chief Financial Officer

    Mylan

    Ken Parks is Mylan’s chief financial officer and is responsible for all of the company’s global finance functions, including accounting and control, financial planning and analysis, investor relations, treasury and tax.

    He also leads Mylan’s Global Integrated Services organization, which centralizes the management of transaction-intensive Finance, Human Relations, IT and other activities to drive scale, efficiency and consistency. In addition, he heads up Global Data and Strategic Analytics, which provides actionable insights to the company’s leaders as well as analytics solutions to the broader business.

    Parks joined Mylan in June 2016 from WESCO International, a leading provider of electrical, industrial and communication products, where he led all aspects of the finance function.

    Prior to WESCO, Parks spent the majority of his career at United Technologies Corporation (UTC) in a variety of U.S. and international finance roles. He most recently served as the company’s vice president, Finance, for its $7 billion UTC Fire & Security division. Prior to that, he led UTC’s Investor Relations function.

    In addition, Parks also held several roles at UTC's $10 billion Carrier Corporation division, including director, Financial Planning and Analysis (FP&A), and vice president of Operations Finance. He spent four years in Paris as Controller and then as director, FP&A, for Carrier's European, Middle East and Africa operations. Parks spent his early years at UTC in auditing, financial reporting and controllership.

    He began his career at the accounting firm Coopers & Lybrand, where he became a certified public accountant.

    Parks earned a Bachelor of Science degree in accounting from University of Tulsa.
  • Daniel M. Gallagher

    Chief Legal Officer

    Mylan

    Daniel Gallagher is Chief Legal Officer at Mylan, a leading global pharmaceutical company. He has extensive public and private sector experience in regulatory matters, financial markets, and corporate legal affairs and governance. He is a member of the Board of Advisors of the Institute for Law and Economics at the University of Pennsylvania.

    Prior to joining Mylan in 2017, Gallagher served as president of Patomak Global Partners, a financial services consulting firm. From Nov. 2011 to Oct. 2015, he served as a Commissioner of the U.S. Securities and Exchange Commission (SEC). As Commissioner, he called for reform on various corporate governance issues, advocated for conducting a comprehensive holistic review of equity market structure issues, and encouraged building the Commission's fixed income market expertise.

    Gallagher also served on the staff of the SEC in several capacities, including as counsel to both SEC Commissioner Paul Atkins and Chairman Christopher Cox, working on matters involving the Division of Enforcement and the Division of Trading and Markets. Gallagher served as deputy director and co-acting director of the Division of Trading and Markets from 2008 to 2010, where he was on the front lines of the agency's response to the financial crisis, including representing the Commission in the Lehman Brothers liquidation.

    Gallagher has significant private sector experience, having been a partner in the Washington, D.C. office of WilmerHale, and senior vice president and general counsel of Fiserv Securities, Inc.